Vertex to acquire Semma Therapeutics for $950m.

Vetex Pharmaceuticals, a leading biotechnology firm to acquire Semma Therapeutics, a privately held biotechnology company pioneering the use of stem cell-derived human islets as a potentially curative treatment for type 1 diabetes, for $950m in cash. “Vertex has a proven track record of serial innovation and a deep commitment to developing transformative therapies for patients in need. Being a part of Vertex will allow the Semma team to rapidly and effectively advance our cell therapy and delivery approaches to patients who need them.” Bastiano Sanna, Semma President and CEO.